Stock Events

Stock Events

MetaVia 

$1.7500
37
-$0.09-4.89% Friday 20:00
+$0.02+1.14%Friday 23:19After hours

Statistics

Day High
1.77
Day Low
1.77
52W High
19.03
52W Low
0.966
Volume
545
Avg. Volume
-
Mkt Cap
11.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.75
-1.78
-0.81
0.16
Expected EPS
-0.733333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-12.97MNet Income

Analyst Ratings

20.00Average Price Target
The highest estimate is 20.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MTVA. It's not an investment recommendation.
Beyond Meat
4
BYND
Microsoft
3
MSFT
Tesla
3
TSLA
Amazon
3
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on neurodegenerative diseases, directly competing in NeuroBo's therapeutic areas.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes works on central nervous system (CNS) diseases, competing in the same therapeutic area as NeuroBo.
Acadia Pharmaceuticals
ACAD
Mkt Cap5.02B
Acadia Pharmaceuticals targets central nervous system disorders, making it a direct competitor in NeuroBo's market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a broad portfolio that includes treatments for neurological disorders, competing with NeuroBo's products.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals develops drugs for neurological disorders, directly competing with NeuroBo's research and development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals, though primarily known for cystic fibrosis treatments, is expanding into other areas including neurological disorders, potentially competing with NeuroBo.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals has a diverse portfolio that includes treatments for neurodegenerative diseases, making it a competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a wide range of healthcare solutions including treatments for neurological conditions, competing with NeuroBo.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio of medicines, including for neurological conditions, making it a competitor in the same therapeutic area as NeuroBo.

About

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
Show more...
CEO
Hyung Heon Kim
Employees
8
Country
United States
ISIN
US64132R5037

Listings

XNAS
US
MTVA
BOATS
BOATS
MTVA.BOATS

0 Comments

Share your thoughts

FAQ

What is MetaVia stock price today?▼
The current price of MTVA is $1.75 USD — it has decreased by -4.89% in the past 24 hours. Watch MetaVia stock price performance more closely on the chart.
What is MetaVia stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange MetaVia stocks are traded under the ticker MTVA.
Is MetaVia stock price growing?▼
MTVA stock has risen by +2.94% compared to the previous week, the month change is a +17.45% rise, over the last year MetaVia has showed a -76.94% decrease.
What is MetaVia market cap?▼
Today MetaVia has the market capitalization of 11.53M
When is the next MetaVia earnings date?▼
MetaVia is going to release the next earnings report on November 16, 2026.
What were MetaVia earnings last quarter?▼
MTVA earnings for the last quarter are -0.9 USD per share, whereas the estimation was -0.82 USD resulting in a -9.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is MetaVia revenue for the last year?▼
MetaVia revenue for the last year amounts to 0 USD.
What is MetaVia net income for the last year?▼
MTVA net income for the last year is -12.97M USD.
How many employees does MetaVia have?▼
As of September 05, 2026, the company has 8 employees.
In which sector is MetaVia located?▼
MetaVia operates in the Health & Wellness sector.
When did MetaVia complete a stock split?▼
The last stock split for MetaVia was on December 05, 2025 with a ratio of 1:11.
Where is MetaVia headquartered?▼
MetaVia is headquartered in CAMBRIDGE, United States.